Doctor profile · Federal record
Dr. Minal Shah, M.D.
Hematology & Oncology Physician (CMS: Hematology/Oncology) · California, MD
- NPI 1265683171
- Accepts Medicare
- MIPS 77.5 / 100 · 2023
- 30 yrs in practice
- Female
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
23415 Three Notch RD Ste 2050
California, MD 206194018
(301) 373-7800
fax (301) 373-6800
Credentials & registration
- NPI registered
- October 2008 — 18 yrs on file
- Profile last updated
- December 14, 2021
- Year of graduation
- 1996 — 30 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Maryland #D0068120
- Medicaid
- MD #417273600
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1265683171. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
221,538
Distinct HCPCS
10
Medicare allowed
$2,633,353
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 75,990 | 70 | $1 | |
J1453 |
Injection, fosaprepitant, 1 mg | 35,850 | 37 | $0 | |
J9271 |
Injection, pembrolizumab, 1 mg | 23,400 | 12 | $54 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 17,010 | 12 | $0 | |
J9267 |
Injection, paclitaxel, 1 mg | 13,126 | 13 | $0 | |
J0897 |
Injection, denosumab, 1 mg | 8,280 | 21 | $23 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 7,181 | 73 | $0 | |
J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units | 6,160 | 30 | $7 | |
J2469 |
Injection, palonosetron hcl, 25 mcg | 5,071 | 66 | $1 | |
J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 3,144 | 46 | $100 |
In context: peer comparison
Among 2 peers in California Hematology & Oncology Physician, average services per provider: 2,943. This provider delivers 75× the peer median.Open Payments
Industry payments received
All-time total
$2,363
Transactions
72
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Janssen Biotech, INC. | 13 | $385.76 | |
| Pfizer INC. | 14 | $318.69 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $245.14 | |
| Merck Sharp & Dohme LLC | 7 | $133.11 | |
| Celgene Corporation | 5 | $108.81 | |
| Karyopharm Therapeutics INC. | 3 | $75.34 | |
| Ipsen Biopharmaceuticals, INC | 3 | $73.34 | |
| Taiho Oncology, INC. | 3 | $70.45 | |
| Exelixis INC. | 3 | $68.33 | |
| Rigel Pharmaceuticals, INC. | 3 | $65.61 | |
| Coherus Biosciences INC. | 3 | $64.75 | |
| Puma Biotechnology, INC. | 3 | $63.35 | |
| Lilly USA, LLC | 3 | $61.82 | |
| Genzyme Corporation | 2 | $61.07 | |
| AstraZeneca Pharmaceuticals Lp | 2 | $56.98 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
419
Patients
105
Total drug cost
$2,070,446
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Anastrozole | Generic | 98 | 33 | $3,339 |
| Prochlorperazine Maleate | Generic | 37 | 26 | $666 |
| Alendronate Sodium | Generic | 34 | 13 | $339 |
| Eliquis (Apixaban) | Brand | 34 | 18 | $38,282 |
| Verzenio (Abemaciclib) | Brand | 33 | 0 | $543,632 |
| Lenalidomide | Generic | 29 | 0 | $451,183 |
| Dexamethasone | Generic | 25 | 15 | $436 |
| Opdivo (Nivolumab) | Brand | 24 | 0 | $354,375 |
| Erleada (Apalutamide) | Brand | 20 | 0 | $319,854 |
| Letrozole | Generic | 16 | 0 | $717 |
Hospital affiliations
Frequently asked questions
What is Dr. Minal Shah's medical specialty?
Dr. Minal Shah practices Hematology & Oncology Physician in California, MD.
Where does Dr. Minal Shah practice?
Dr. Minal Shah practices at 23415 Three Notch RD Ste 2050, California, MD 206194018. Office phone: 3013737800.
What is Dr. Minal Shah's NPI?
Dr. Minal Shah's National Provider Identifier (NPI) is 1265683171, issued by NPPES.
Does Dr. Minal Shah accept Medicare assignment?
Yes. Dr. Minal Shah accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Minal Shah commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, fosaprepitant, 1 mg (HCPCS J1453); Injection, pembrolizumab, 1 mg (HCPCS J9271). Source: CMS Medicare Physician & Other Practitioners file.